Advanced search
Publication Cover
Clinical Epidemiology Volume 8, 2016 - Issue
Submit an article Journal homepage
114
Views
29
CrossRef citations to date
0
Altmetric
Review

The Danish Multiple Sclerosis Treatment Register

Melinda Magyari1 Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Copenhagen;3 Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
,
Nils Koch-Henriksen1 Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Copenhagen;2 Department of Clinical Epidemiology, Clinical Institute, University of Aarhus, Aarhus
&
Per Soelberg Sørensen3 Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Pages 549-552 | Published online: 25 Oct 2016

References

  • SørensenPSNew management algorithms in multiple sclerosisCurr Opin Neurol20142724625924759080
  • Koch-HenriksenNMagyariMLaursenBRegisters of multiple sclerosis in DenmarkActa Neurol Scand Suppl2015132410
  • Koch-HenriksenNSørensenPSThe Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis GroupMult Scler2000617217510871828
  • SørensenPSKoch-HenriksenNRavnborgMImmunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide surveyMult Scler20061225326416764337
  • SørensenPSRossCClemmesenKMAntibodies to IFN-beta: the Danish National IFN-beta ProjectNeurology200361S27S28
  • SørensenPSRossCClemmesenKMClinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisLancet20033621184119114568740
  • Koch-HenriksenNSørensenPSBendtzenKFlachsEMThe clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosisMult Scler20091560160519299439
  • JensenPEKoch-HenriksenNSellebjergFSørensenPSPrediction of antibody persistency from antibody titres to natalizumabMult Scler2012181493149922454098
  • SørensenPSDeisenhammerFDudaPGuidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosisEur J Neurol20051281782716241970
  • MagyariMKoch-HenriksenNLaursenBSørensenPSGender effects on treatment response to interferon-beta in multiple sclerosisActa Neurol Scand201413037437925208455
  • SellebjergFSøndergaardHBKoch-HenriksenNSørensenPSOturaiABPrediction of response to interferon therapy in multiple sclerosisActa Neurol Scand201413026827524943672
  • OturaiABKoch-HenriksenNPetersenTJensenPESellebjergFSørensenPSEfficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide studyEur J Neurol20091642042319364368
  • SørensenPSKoch-HenriksenNPetersenTRavnborgMOturaiASellebjergFRecurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patientsJ Neurol20142611170117724728334

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.